Trial Profile

A study analyzing absorption, metabolism, and excretion of ONC201 in humans

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dordaviprone (Primary)
Indications Acute myeloid leukaemia; Adenocarcinoma; Breast cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Glioblastoma; Liver cancer; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal failure; Sarcoma; Small cell lung cancer; Thyroid cancer
Focus Pharmacokinetics

Most Recent Events

22 May 2024 New trial record
29 Mar 2024 Results presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com